TIMOPTOL Eye drops, solution (2018)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Timoptol 0.25% w/v eye drops, solution. Timoptol 0.5% w/v eye drops, solution.
Qualitative and quantitative composition
Each millilitre of 0.25% w/v solution contains an amount of timolol maleate equivalent to 2.5 mg timolol. Each millilitre of 0.5% w/v solution contains an amount of timolol maleate equivalent to 5 mg timolol. ...
Pharmaceutical form
Eye drops, solution. Clear, colourless to light yellow, sterile eye drops, solution.
Therapeutic indications
Timoptol is a beta-adrenoreceptor blocking agent used topically in the reduction of elevated intra-ocular pressure in various conditions including following: patients with ocular hypertension; patients ...
Posology and method of administration
Posology Recommended therapy is one drop 0.25% solution in the affected eye twice a day. If clinical response is not adequate, dosage may be changed to one drop 0.5% solution in each affected eye twice ...
Contraindications
Reactive airway disease including bronchial asthma or a history of bronchial asthma, severe chronic obstructive pulmonary disease; sinus bradycardia, sick sinus syndrome sino-atrial block, second- and ...
Special warnings and precautions for use
Like other topically applied ophthalmic agents, timolol is absorbed systemically. Due to beta-adrenergic component, timolol, the same types of cardiovascular, pulmonary and other adverse reactions seen ...
Interaction with other medicinal products and other forms of interaction
No specific drug interaction studies have been performed with timolol maleate. There is a potential for additive effects resulting in hypotension and/or marked bradycardia when ophthalmic beta-blockers ...
Pregnancy and lactation
Pregnancy There are no adequate data for the use of timolol maleate in pregnant women. Timoptol should not be used during pregnancy unless clearly necessary. To reduce the systemic absorption, see section ...
Effects on ability to drive and use machines
Possible side effects such as dizziness, visual disturbances, refractive changes, diplopia, ptosis, frequent episodes of mild and transient blurred vision and fatigue may affect some patients' ability ...
Undesirable effects
Like other topically applied ophthalmic drugs, timolol is absorbed into the systemic circulation. This may cause similar undesirable effects as seen with systemic beta-blocking agents. Incidence of systemic ...
Overdose
There have been reports of inadvertent overdosage with Timoptol resulting in systemic effects similar to those seen with systemic beta-adrenergic blocking agents such as dizziness, headache, shortness ...
Pharmacodynamic properties
Pharmacotherapeutic group: Ophthalmologicals, antiglaucoma preparations and miotics, betablocking agents ATC code: S01ED01 Mechanism of action Timolol maleate is a non-selective beta-adrenergic receptor ...
Pharmacokinetic properties
The onset of reduction in intra-ocular pressure can be detected within one-half hour after a single dose. The maximum effect occurs in one or two hours; significant lowering of IOP can be maintained for ...
Preclinical safety data
No adverse ocular effects were observed in rabbits and dogs administered Timoptol topically in studies lasting one and two years, respectively. The oral LD<sub>50</sub> of the drug is 1,190 and 900 mg/kg ...
List of excipients
Disodium phosphate dodecahydrate Sodium dihydrogen phosphate dihydrate Sodium hydroxide Benzalkonium chloride Water for injections
Incompatibilities
None known.
Shelf life
36 months. Discard solution 28 days after opening the bottle.
Special precautions for storage
Do not store above 25°C. Store the bottle in the outer carton in order to protect from light.
Nature and contents of container
Timoptol Eye Drops Solution bottle contains 5 ml of solution. Two alternative bottles may be marketed. White translucent low-density polyethylene (LDPE) bottle with a transparent linear LDPE dropper tip ...
Special precautions for disposal and other handling
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Marketing authorization holder
Santen Oy, Niittyhaankatu 20, 33720, Tampere, Finland
Marketing authorization number(s)
0.25% w/v eye drops, solution: PL 16058/0020 0.5% w/v eye drops, solution: PL 16058/0019
Date of first authorization / renewal of the authorization
Date of first authorisation: 5 January 1979 Date of the latest renewal: 5 March 2010
Date of revision of the text
16/11/2018
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: